News
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...
We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...
Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...
Rhythm Pharmaceuticals develops medicines for rare disorders that cause weight gain. The company's only approved product is ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...
Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
1d
Money Talks News on MSNAre Your Weight-Loss Drugs Real? Novo Nordisk Sounds Alarm on Knockoffs
One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
1d
GlobalData on MSNFangzhou and Novo Nordisk link on chronic disease management
The joint effort will focus on providing patients with medication guidance, reminders, tracking of efficacy and health education.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results